Global Melanoma Therapeutics Market to Reach $1.1 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on melanoma therapeutics markets. The world market for melanoma therapeutics is projected to reach $1.1 billion by 2015. This is primarily driven by rapid rise in the number of people suffering from melanoma of skin, due to increased exposure to UV rays and depletion of ozone layer. Additionally, R&D initiatives to discover and develop new treatment options will contribute to market growth.

Melanoma Therapeutics: A Global Strategic Business Report

Melanoma is a form of cancer that typically develops in melanocytes, the melanin-generating cells. Melanoma of skin or otherwise cutaneous melanoma is the most common type of melanoma, as greater proportion of melanocytes cells primarily resides in the skin. Both environmental and intrinsic risk factors increase a person's chance of inheriting melanoma. Overexposure to sun is a significant environmental factor contributing for melanoma development. Individuals with a family history of melanoma are also more likely to inherit the disease.

The United States dominates the world melanoma therapeutics market as stated by the new market research report on Melanoma Therapeutics market. Melanoma represents the most lethal form of skin cancers in the US. Incidence of melanoma has almost doubled during the past thirty years, and is increasing continually, claiming the life of one individual every hour. Melanoma cancer market presents immense commercial opportunities for drug developers, specifically to address unmet medical needs in metastatic condition.

Though there exists no effective treatment for patients with advanced metastatic melanoma, more often the FDA approved chemotherapeutic agent, Dacarbazine and biologic agent Interleukin-2 (IL-2) are used. Pfizer's investigational drug, Tremelimumab, for use in advanced melanoma treatment, provides a ray of hope for patients with unresectable Stage IV melanoma.

Key players profiled in the report include Abraxis BioScience Inc., Astellas Pharma US Inc., Antigenics Inc., AVAX Technologies Inc., BioVex Inc., GenVec Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Vical, Inc.

The report titled "Melanoma Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of overview of melanoma cancer treatment, global and regional market overview, pipeline analysis, investigational drugs, drugs under various clinical trials, discontinued trials, R&D initiatives, mergers and acquisitions, and recent corporate initiatives. The study analyzes market data and analytics in terms of value sales for the United States, and Rest of World markets.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website